267 related articles for article (PubMed ID: 11046097)
1. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
2. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.
Raut R; Rouleau JL; Blais C; Gosselin H; Molinaro G; Sirois MG; Lepage Y; Crine P; Adam A
Am J Physiol; 1999 May; 276(5):H1769-79. PubMed ID: 10330262
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
4. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
Dumoulin MJ; Adam A; Burnett J; Heublein D; Yamaguchi N; Lamontagne D
Can J Physiol Pharmacol; 2005 Feb; 83(2):166-73. PubMed ID: 15791290
[TBL] [Abstract][Full Text] [Related]
5. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
7. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
[TBL] [Abstract][Full Text] [Related]
8. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.
Kokkonen JO; Kuoppala A; Saarinen J; Lindstedt KA; Kovanen PT
Circulation; 1999 Apr; 99(15):1984-90. PubMed ID: 10209002
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Dumoulin MJ; Adam A; Rouleau JL; Gosselin H; Lamontagne D
Can J Physiol Pharmacol; 2003 Jul; 81(7):740-6. PubMed ID: 12897822
[TBL] [Abstract][Full Text] [Related]
10. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
12. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
Heudi O; Ramirez-Molina C; Marshall P; Amour A; Peace S; McKeown S; Abou-Shakra F
J Pept Sci; 2002 Nov; 8(11):591-600. PubMed ID: 12487427
[TBL] [Abstract][Full Text] [Related]
13. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
14. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
15. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
[TBL] [Abstract][Full Text] [Related]
16. Local inhibition of bradykinin degradation in ischemic hearts.
Linz W; Martorana PA; Schölkens BA
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
[TBL] [Abstract][Full Text] [Related]
19. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
20. Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.
Adam A; Leclair P; Montpas N; Koumbadinga GA; Bachelard H; Marceau F
Neuropeptides; 2010 Apr; 44(2):69-75. PubMed ID: 19836835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
